New hope for kids with untreatable autoimmune diseases
NCT ID NCT07184450
Summary
This is an early-stage study testing a new type of cell therapy called BCMA/CD70 CAR-T for children with severe rheumatic diseases that have not responded to standard treatments. The trial aims to see if this therapy is safe and can reduce disease activity in conditions like juvenile arthritis, dermatomyositis, scleroderma, and Sjogren's syndrome. Researchers will modify the child's own immune cells to target and potentially control the overactive immune response causing their illness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS (SSC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.